X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (37) 37
index medicus (26) 26
oncology (22) 22
animals (12) 12
female (11) 11
male (11) 11
lung neoplasms - drug therapy (9) 9
cell line, tumor (8) 8
antineoplastic agents - pharmacology (7) 7
article (7) 7
lung neoplasms - genetics (7) 7
middle aged (7) 7
lung neoplasms - pathology (6) 6
abridged index medicus (5) 5
adult (5) 5
aged (5) 5
antineoplastic agents - therapeutic use (5) 5
biochemistry & molecular biology (5) 5
cancer (5) 5
care and treatment (5) 5
cell lung-cancer (5) 5
chemotherapy (5) 5
mice (5) 5
research (5) 5
acquired-resistance (4) 4
activation (4) 4
breast cancer (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
lung cancer (4) 4
messenger-rna translation (4) 4
mutation (4) 4
mutations (4) 4
phosphorylation - drug effects (4) 4
protein kinase inhibitors - therapeutic use (4) 4
protein-serine-threonine kinases - metabolism (4) 4
signal transduction (4) 4
tor serine-threonine kinases (4) 4
tumors (4) 4
acute promyelocytic leukemia (3) 3
adenocarcinoma (3) 3
adenocarcinoma - pathology (3) 3
aged, 80 and over (3) 3
arsenicals - pharmacology (3) 3
brain tumors (3) 3
cancer biology (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
carcinoma, squamous cell - genetics (3) 3
carcinoma, squamous cell - pathology (3) 3
cell biology (3) 3
cell proliferation (3) 3
cell proliferation - drug effects (3) 3
chronic myeloid-leukemia (3) 3
disease progression (3) 3
dose-response relationship, drug (3) 3
drug resistance (3) 3
drug resistance, neoplasm - genetics (3) 3
enzyme inhibitors - pharmacology (3) 3
gene expression regulation, neoplastic (3) 3
gene-expression (3) 3
hematology (3) 3
induced apoptosis (3) 3
k562 cells (3) 3
kaplan-meier estimate (3) 3
melanoma (3) 3
multidisciplinary sciences (3) 3
oxides - pharmacology (3) 3
physiological aspects (3) 3
proteins - antagonists & inhibitors (3) 3
proto-oncogene proteins p21 - genetics (3) 3
resistance (3) 3
therapy (3) 3
tumor cells, cultured (3) 3
1st-line treatment (2) 2
activated protein-kinase (2) 2
adenocarcinoma - genetics (2) 2
adenocarcinoma - metabolism (2) 2
androgen antagonists - adverse effects (2) 2
androgen antagonists - therapeutic use (2) 2
androgen suppression therapy (2) 2
anti-estrogen therapy (2) 2
apoptosis - drug effects (2) 2
biomedical research (2) 2
bone-marrow (2) 2
brain metastases (2) 2
brain neoplasms - secondary (2) 2
breast and prostate cancers (2) 2
breast neoplasms - mortality (2) 2
breast neoplasms - pathology (2) 2
breast neoplasms - therapy (2) 2
breast-cancer (2) 2
carcinoma, squamous cell - metabolism (2) 2
cardiovascular diseases - physiopathology (2) 2
chronic myelogenous leukemia (2) 2
combination (2) 2
complications and side effects (2) 2
crispr-cas9 (2) 2
egfr (2) 2
enhancer of zeste homolog 2 protein - genetics (2) 2
enhancer of zeste homolog 2 protein - metabolism (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 07/2011, Volume 306, Issue 3, p. 247
Redig recounts her experience as a physician under constant physical, cognitive, and emotional strain. In the ten years since the traumatic brain injury and... 
Neurology | Personal health | Confidentiality | Epilepsy | Brain damage | Emergency medical care
Journal Article
JAMA, ISSN 0098-7484, 07/2011, Volume 306, Issue 3, pp. 247 - 248
Journal Article
Journal Article
Academic medicine : journal of the Association of American Medical Colleges, ISSN 1040-2446, 2009, Volume 84, Issue 5, p. 565
Journal Article
Health affairs (Project Hope), ISSN 0278-2715, 2009, Volume 28, Issue 5, pp. 1515 - 1520
  The author has the numbers memorized: first the phone number for a claims adjuster, then the policy number for the person who takes her call. The truth is... 
HEALTH POLICY & SERVICES | HEALTH CARE SCIENCES & SERVICES | Insurance, Health, Reimbursement | Emergency Service, Hospital - economics | Students, Medical | Insurance Claim Reporting | Humans | Health insurance | Billings | Health care expenditures | Insurance claims | Health care policy
Journal Article
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 12/2017, Volume 6, Issue Suppl 1, pp. S58 - S61
Journal Article
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 08/2010, Volume 24, Issue 9, pp. 839 - 844
The incidence of metabolic syndrome is rapidly increasing. Metabolic syndrome is associated with elevated morbidity and mortality secondary to cardiovascular... 
ANDROGEN-DEPRIVATION THERAPY | LONG-TERM SURVIVORS | ONCOLOGY | NUTRITION EXAMINATION SURVEY | FATTY LIVER-DISEASE | PROSTATE-CANCER | 3RD NATIONAL-HEALTH | TESTICULAR CANCER | BODY-MASS INDEX | EARLY BREAST-CANCER | RENAL-CELL CARCINOMA | Prostatic Neoplasms - metabolism | Humans | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms - physiopathology | Breast Neoplasms - physiopathology | Breast Neoplasms - metabolism | Prostatic Neoplasms - therapy | Breast Neoplasms - therapy | Metabolic Diseases - therapy | Metabolic Diseases - physiopathology | Antineoplastic Agents - adverse effects | Testicular Neoplasms - physiopathology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Female | Cardiovascular Diseases - etiology | Testicular Neoplasms - therapy | Cardiovascular Diseases - physiopathology | Cardiovascular Diseases - metabolism | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Risk Factors | Insulin Resistance | Metabolic Diseases - epidemiology | Testicular Neoplasms - metabolism | Combined Modality Therapy - adverse effects | Estrogen Antagonists - therapeutic use | Metabolic Diseases - metabolism | Metabolic Diseases - etiology | Estrogen Antagonists - adverse effects | Survival Analysis | Androgen Antagonists - therapeutic use | Hormone Antagonists - therapeutic use | TOR Serine-Threonine Kinases | Androgen Antagonists - adverse effects | Liver Diseases | Hormone Antagonists - adverse effects
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2013, Volume 2013, Issue 1, pp. 377 - 381
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2712 - 2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | ONCOLOGY | ADENOCARCINOMAS | RESISTANCE | OPEN-LABEL | MUTATIONS | TUMORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Molecular Conformation | Receptor, ErbB-2 - chemistry | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Codon | Adult | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Gene Expression | Models, Molecular | Treatment Outcome | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Mutagenesis, Insertional | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | Amino Acid Substitution | Epidermal growth factor receptors | Lung cancer | Insertion | Non-small cell lung carcinoma | Drug resistance | Patients | ErbB-2 protein | Mutants | Sensitivity | Covalence | Inhibitors | Mutation | Tumors | Cancer | human epidermal growth factor receptor 2 | drug resistance | tyrosine kinase inhibitor | exon 20 | Epidermal growth factor receptor
Journal Article
Oncotarget, 08/2016, Volume 7, Issue 33, p. 53997
There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins... 
Neoplasms - metabolism | Animals | Humans | Antineoplastic Agents - pharmacology | Proteins - antagonists & inhibitors | Molecular Targeted Therapy - methods | Neoplasms - drug therapy
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2016, Volume 22, Issue 24, pp. 6010 - 6020
Journal Article
Oncotarget, ISSN 1949-2553, 08/2016, Volume 7, Issue 33, pp. 53997 - 54009
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2011, Volume 17, Issue 13, pp. 4378 - 4388
Journal Article